78 Results
Sort By:
Published on January 5, 2022
When his wife retrieved the Christmas lights from their garage in mid December, Foghorn Therapeutics President and CEO Adrian Gottschalk recalled, the decorations she unpacked presented an apt analogy for explaining the science behind his company, a developer of precision therapies. Just as the string of lights was tangled up…
Published on November 8, 2021
Bayer Pharmaceuticals, and The Life Raft Group (LRG), a non-profit with focused on curing gastrointestinal stromal tumors (GIST) announced today they have extended a research collaboration to broaden access to comprehensive genomic testing GIST patients, with the intent to identify patients who may benefit from precision care. GISTs are a…
Published on September 14, 2021
In a “first of its kind” study, researchers at the University of Illinois, Chicago (UIC) have presented information suggesting a new potential direct link between herpes simplex virus type 1 (HSV-1) and neurodegenerative diseases, such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and glaucoma. The team, led by Deepak Shukla,…
Published on September 7, 2021
Through a collaboration that could be valued to more than $3 billion, Genentech, a member of the Roche Group, announced it will partner with Adaptimmune to develop and commercialize allogeneic T-cell therapies to treat multiple cancer indications. Under their collaboration Genentech will work with Adaptimmune to develop “off-the-shelf” allogeneic T-cell therapies…
Published on August 19, 2021
A team of researchers, led by bioengineers at the Georgia Institute of Technology, has shown that modifying CAR T-cell therapies improves the precision and capabilities of these therapies to be used against solid tumors. The research—published recently in Nature Biomedical Engineering has the potential to broaden the reach of CAR T-cell…
Published on August 5, 2021
For a cell to grow and divide, it needs to produce new proteins. This also applies to cancer cells. In a new study published today in Science Advances, researchers at Karolinska Institutet in Sweden have investigated the protein eukaryotic initiation factor 4A-III (eIF4A3) and its role in the growth of cancer…
Published on June 25, 2021
A large international study investigating the genetics of the rare childhood muscle and soft tissue cancer rhabdomyosarcoma has revealed genetic variants linked with more severe disease that could help researchers develop better targeted therapies in the future. Rhabdomyosarcoma is an aggressive, but relatively rare cancer with approximately 250 cases per…
Published on June 15, 2021
The Biden Administration’s new $1.7 billion commitment to expand genomic sequencing to fight COVID-19 is a welcome step that unfortunately comes late in the course of the pandemic, though of course better to come late than not at all. Yet, given that the infrastructure is still not in place, the…
Published on June 3, 2021
Researchers based at the University of North Carolina at Chapel Hill have discovered that the gene OTUD7A controls a cancer-causing protein in Ewing sarcoma, a type of bone cancer mostly impacting children. The team also uncovered a compound that appears to be able to block the activity of the OTUD7A…
Published on February 16, 2021
Each year, about 16,000 children are diagnosed with cancer. To learn more about , underlying genetic risks for cancer in children, researchers from Memorial Sloan Kettering’s pediatric program tested 751 pediatric patients treated for solid tumors for inherited cancer-associated mutations, or germline mutations. In a paper published in Nature Cancer,…
Published on February 11, 2021
Overcoming drug resistance remains a primary goal in cancer treatment. Researchers at Cincinnati Children’s discovered they could overcome it in a mouse model of glioblastoma, a notoriously refractory tumor type. They discovered that inhibiting the enzyme Stearoyl Co-A Desaturase (SCD) reduced the expression of the protein FBJ murine osteosarcoma viral…
Published on August 25, 2020
A team of investigators at the Children’s Hospital of Philadelphia (CHOP) has released new data describing an enhanced treatment that leads to long-term remissions in 80–100% of mice with drug-resistant or high-risk solid tumors. Findings from the new study were published recently in Cancer Research through an article titled, “Structural Optimization…
Published on August 18, 2020
Human cells have twenty-three pairs of chromosomes but in cancer, genes can be amplified in chromosomes or in circular extrachromosomal DNA (ecDNA), whose frequency and functional significance are not yet understood. Now researchers at the University of California (UC), San Diego, report that ecDNA is a common event in human…
Published on July 17, 2020
Rare inherited mutations in the TP53 gene can leave people at a higher risk of developing multiple types of cancer over the course of their lives. Now, a team led by researchers in the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania details the…
Published on December 31, 2019
Alex Trebek appeared well en route to surviving pancreatic cancer this past summer when his doctors followed up his initial successful chemotherapy with an undisclosed immunotherapy. That move backfired. “I was doing so well. And my numbers went down to the equivalent of a normal human being who does not…